The new product line includes Sermorelin, NAD+, Glutathione and MIC/B6/B12 to help meet demand as physicians and patients focus more on preventative health measures
ProRx Pharma, the health and wellness 503B outsourcing facility, recently announced the launch of four new injectables in its health and wellness product line: Sermorelin, NAD+, Glutathione and MIC/B6/B12. These new offerings are now available with bulk shipping to 26 states exclusively through partners such as 503A pharmacies, medical clinics, med spas and telemedicine practices as well as direct-to-patient shipping in 50 states.
“Patients are increasingly seeking proactive healthcare approaches, and physicians are emphasizing preventative care more than ever,” said Kurt Lunkwitz, Chief Operating Officer at ProRx. “The growing trend of physicians integrating health and wellness into their practices, especially those in preventative and functional medicine, is driven by mass adoption, patient interest and the strong need to address patients’ demands for more preventative and holistic care. ProRx is playing an important role by supporting the healthcare community as they seek to improve people’s lives with easier access to a full product line of medications that aim to support their preventative health needs.”
The four new offerings are standalone, injectable products with their own National Drug Code (NDC) number and Beyond Use Dates (BUD) of 3-12 months:
- Sermorelin: (Growth hormone peptide)
- NAD+: (Cellular coenzyme antioxidant)
- Glutathione: (antioxidant)
- MIC/B6/B12: (Lipotropic amino acid)
In February, ProRx announced the expansion of its operations to a total of 6,888 square feet, essentially doubling the square footage of its pharmaceutical and manufacturing facility. The new facility with more production space allows ProRx to triple its manufacturing capabilities and enhance operational processes that will further strengthen compliance with compounding lab Standard Operating Procedures (SOPs) and the FDA.
“ProRX ProRx has been a long-term, trusted partner for a number of healthcare organizations,” said Lunkwitz. “Our quality of base materials, testing requirements, evaluation and SOPs allow us to produce higher quality products with longer beyond use dates and come with NDC codes. It’s a testament to the expertise of the ProRx team and our dedication to serve our healthcare partners that we were able to get these medications into production and streamlined for release so quickly.”
As part of its strategic rebranding and expansion under new leadership, ProRx has welcomed new team members with over 50 years of collective pharmaceutical and healthcare experience, further reinforcing ProRx’s commitment to stringent regulatory compliance, quality assurance, and preventative health solutions.
About ProRx Pharma
ProRx Pharma is an FDA-registered cGMP facility focused on providing essential compounded medications to meet the need for medications on the FDA drug shortage and bulks list with an emphasis on preventative health. The company produces products and formulations for medical institutions and physician offices, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages. For more information, visit https://prorxpharma.com/.
The Editorial Team at Healthcare Business Today is made up of experienced healthcare writers and editors, led by managing editor Daniel Casciato, who has over 25 years of experience in healthcare journalism. Since 1998, our team has delivered trusted, high-quality health and wellness content across numerous platforms.
Disclaimer: The content on this site is for general informational purposes only and is not intended as medical, legal, or financial advice. No content published here should be construed as a substitute for professional advice, diagnosis, or treatment. Always consult with a qualified healthcare or legal professional regarding your specific needs.
See our full disclaimer for more details.
